Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Avalo Therapeutics (AVTX) FCF Margin (2016 - 2024)

Historic FCF Margin for Avalo Therapeutics (AVTX) over the last 10 years, with Q4 2024 value amounting to 7858.33%.

  • Avalo Therapeutics' FCF Margin fell 73739200.0% to 7858.33% in Q4 2024 from the same period last year, while for Sep 2025 it was 27239.58%, marking a year-over-year decrease of 227544600.0%. This contributed to the annual value of 11133.79% for FY2024, which is 95309800.0% down from last year.
  • According to the latest figures from Q4 2024, Avalo Therapeutics' FCF Margin is 7858.33%, which was down 73739200.0% from 4629.32% recorded in Q3 2024.
  • Over the past 5 years, Avalo Therapeutics' FCF Margin peaked at 38.04% during Q3 2022, and registered a low of 7858.33% during Q4 2024.
  • For the 5-year period, Avalo Therapeutics' FCF Margin averaged around 2170.73%, with its median value being 1212.63% (2021).
  • As far as peak fluctuations go, Avalo Therapeutics' FCF Margin skyrocketed by 73730500bps in 2022, and later tumbled by -73739200bps in 2024.
  • Over the past 5 years, Avalo Therapeutics' FCF Margin (Quarter) stood at 960.25% in 2020, then plummeted by -714bps to 7812.79% in 2021, then soared by 94bps to 439.73% in 2022, then dropped by -10bps to 484.41% in 2023, then tumbled by -1522bps to 7858.33% in 2024.
  • Its FCF Margin was 7858.33% in Q4 2024, compared to 4629.32% in Q3 2024 and 484.41% in Q4 2023.